BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 16406782)

  • 21. Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase.
    Heikkilä T; Ramsey C; Davies M; Galtier C; Stead AM; Johnson AP; Fishwick CW; Boa AN; McConkey GA
    J Med Chem; 2007 Jan; 50(2):186-91. PubMed ID: 17228860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases.
    Davies M; Heikkilä T; McConkey GA; Fishwick CW; Parsons MR; Johnson AP
    J Med Chem; 2009 May; 52(9):2683-93. PubMed ID: 19351152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biphenyl-4-ylcarbamoyl thiophene carboxylic acids as potent DHODH inhibitors.
    Leban J; Kralik M; Mies J; Baumgartner R; Gassen M; Tasler S
    Bioorg Med Chem Lett; 2006 Jan; 16(2):267-70. PubMed ID: 16246558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents.
    Liu S; Neidhardt EA; Grossman TH; Ocain T; Clardy J
    Structure; 2000 Jan; 8(1):25-33. PubMed ID: 10673429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In-Silico molecular docking and simulation studies on novel chalcone and flavone hybrid derivatives with 1, 2, 3-triazole linkage as vital inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
    Thillainayagam M; Malathi K; Ramaiah S
    J Biomol Struct Dyn; 2018 Nov; 36(15):3993-4009. PubMed ID: 29132266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of novel inhibitors for DHODH via virtual screening and X-ray crystallographic structures.
    McLean LR; Zhang Y; Degnen W; Peppard J; Cabel D; Zou C; Tsay JT; Subramaniam A; Vaz RJ; Li Y
    Bioorg Med Chem Lett; 2010 Mar; 20(6):1981-4. PubMed ID: 20153645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis, Design, and Structure⁻Activity Relationship of the Pyrimidone Derivatives as Novel Selective Inhibitors of
    Xu L; Li W; Diao Y; Sun H; Li H; Zhu L; Zhou H; Zhao Z
    Molecules; 2018 May; 23(6):. PubMed ID: 29794978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemometric modeling, docking and in silico design of triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors as antimalarials.
    Ojha PK; Roy K
    Eur J Med Chem; 2010 Oct; 45(10):4645-56. PubMed ID: 20708304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode.
    Zeng T; Zuo Z; Luo Y; Zhao Y; Yu Y; Chen Q
    FEBS Open Bio; 2019 Aug; 9(8):1348-1354. PubMed ID: 31087527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel insights for dihydroorotate dehydrogenase class 1A inhibitors discovery.
    Cheleski J; Rocha JR; Pinheiro MP; Wiggers HJ; da Silva AB; Nonato MC; Montanari CA
    Eur J Med Chem; 2010 Dec; 45(12):5899-909. PubMed ID: 20965617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of 7-arylaminopyrazolo[1,5-a]pyrimidines as anti-Plasmodium falciparum, antimalarial, and Pf-dihydroorotate dehydrogenase inhibitors.
    Azeredo LFSP; Coutinho JP; Jabor VAP; Feliciano PR; Nonato MC; Kaiser CR; Menezes CMS; Hammes ASO; Caffarena ER; Hoelz LVB; de Souza NB; Pereira GAN; Cerávolo IP; Krettli AU; Boechat N
    Eur J Med Chem; 2017 Jan; 126():72-83. PubMed ID: 27744189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases.
    Leban J; Vitt D
    Arzneimittelforschung; 2011; 61(1):66-72. PubMed ID: 21355448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis.
    He T; Haapa-Paananen S; Kaminskyy VO; Kohonen P; Fey V; Zhivotovsky B; Kallioniemi O; Perälä M
    Oncogene; 2014 Jul; 33(27):3538-49. PubMed ID: 24013224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: Synthesis, biological evaluation and X-ray structural studies.
    Pippione AC; Sainas S; Goyal P; Fritzson I; Cassiano GC; Giraudo A; Giorgis M; Tavella TA; Bagnati R; Rolando B; Caing-Carlsson R; Costa FTM; Andrade CH; Al-Karadaghi S; Boschi D; Friemann R; Lolli ML
    Eur J Med Chem; 2019 Feb; 163():266-280. PubMed ID: 30529545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dihydroorotate dehydrogenase inhibitors in anti-infective drug research.
    Boschi D; Pippione AC; Sainas S; Lolli ML
    Eur J Med Chem; 2019 Dec; 183():111681. PubMed ID: 31557612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
    Knecht W; Löffler M
    Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds.
    Deng X; Gujjar R; El Mazouni F; Kaminsky W; Malmquist NA; Goldsmith EJ; Rathod PK; Phillips MA
    J Biol Chem; 2009 Sep; 284(39):26999-7009. PubMed ID: 19640844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds.
    Sainas S; Pippione AC; Giorgis M; Lupino E; Goyal P; Ramondetti C; Buccinnà B; Piccinini M; Braga RC; Andrade CH; Andersson M; Moritzer AC; Friemann R; Mensa S; Al-Kadaraghi S; Boschi D; Lolli ML
    Eur J Med Chem; 2017 Mar; 129():287-302. PubMed ID: 28235702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The X-ray structure of Plasmodium falciparum dihydroorotate dehydrogenase bound to a potent and selective N-phenylbenzamide inhibitor reveals novel binding-site interactions.
    Deng X; Matthews D; Rathod PK; Phillips MA
    Acta Crystallogr F Struct Biol Commun; 2015 May; 71(Pt 5):553-9. PubMed ID: 25945708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interconvertible geometric isomers of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors exhibit multiple binding modes.
    McConkey GA; Bedingfield PTP; Burrell DR; Chambers NC; Cunningham F; Prior TJ; Fishwick CWG; Boa AN
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3878-3882. PubMed ID: 28669445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.